NEOADJUVANT

作品数：272被引量：1427H指数：17
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：金征宇王志伟胡晓桦沈怡戴培东更多>>
相关机构：北京协和医院广西医科大学第一附属医院华中科技大学济南市第三人民医院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Hypercoagulation after neoadjuvant immunochemotherapy as a new prognostic indicator in patients with locally advanced gastric cancer undergoing surgery
《World Journal of Gastrointestinal Oncology》2025年第3期91-103,共13页Tian-Hao Li Xiong Sun Cheng-Guo Li Yu-Ping Yin Kai-Xiong Tao 
Natural Science Foundation of Hubei Province of China,No.2024AFB655;Key Research and Development Program of Hubei Province of China,No.2021BCA116;National Natural Science Foundation of China,No.82072736,No.82003205,No.
BACKGROUND Coagulation status is closely related to the progression of malignant tumors.In the era of neoadjuvant immunochemotherapy(NICT),the prognostic utility of coagulation indicators in patients with locally adva...
关键词：Locally advanced gastric cancer COAGULATION Neoadjuvant immunochemotherapy PROGNOSIS Radical gastrectomy 
Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma:A narrative review
《Current Urology》2025年第1期39-42,共4页Sentai Ding Chenrui Wu Jishuang Cao Jiaju Lyu 
supported by Shandong Provincial Natural Science Foundation(ZR2023LZL005);Jinan Science and Technology Development Foundation.
Immunotherapy has become a standard treatment for patients with advanced urothelial carcinoma,and neoadjuvant immunotherapy is currently being extensively explored.This reviewhighlights the initial findings and key cl...
关键词：Muscle-invasive bladder cancer Immune checkpoint inhibitor Tislelizumab Neoadjuvant immunotherapy 
Immunotherapy and liver transplantation for hepatocellular carcinoma:Current and future challenges
《World Journal of Transplantation》2025年第2期8-29,共22页Theodoros Pettas Sofia Lachanoudi Filippos F Karageorgos Ioannis A Ziogas Asimina Fylaktou Vassilios Papalois Georgios Katsanos Nikolaos Antoniadis Georgios Tsoulfas 
Despite existing curative options like surgical removal,tissue destruction techniques,and liver transplantation for early-stage hepatocellular carcinoma(HCC),the rising incidence and mortality rates of this global hea...
关键词：Hepatocellular carcinoma IMMUNOTHERAPY Liver transplantation Neoadjuvant and adjuvant immunotherapy Immune checkpoint inhibitors Vaccine therapies Oncolytic viruses Adoptive cell therapy Antigen-targeting antibodies Diagnostic biomarkers 
Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers
《Cancer Communications》2025年第2期198-202,共5页Gavin P.Dowling Gordon R.Daly Aisling Hegarty Michael Flanagan Mihaela Ola Ramón Fallon Sinéad Cocchiglia Vikrant Singh Katherine M.Sheehan Fiona Bane Jason McGrath Louise Watson Sandra Hembrecht Bryan Hennessy Patrick G.Morris Arnold D.K.Hill Damir Varešlija Leonie S.Young 
support from Science Foundation Ireland Frontiers for the Future Award(19/FFP/6443);Science Foundation Ireland Strategic Partnership Program,Precision Oncology Ireland(18/SPP/3522)(L.S.Y.);Breast Cancer Now Fellowship Award with the generous support of Walk the Walk(2019AugSF1310)(D.V.);Science Foundation Ireland(20/FFP-P/8597)(D.V.);Breast Cancer Ireland program Grant(18239A01)(L.S.Y.).
The expression of estrogen receptor(ER)and human epidermal growth factor receptor-2(HER2)in breast cancer can change in response to treatment and pivotally influence tumor behavior and clinical management[1].Receptor ...
关键词：alterations HER2 BREAST 
Evaluating the predictive value of endoscopic findings for residual colorectal cancer following neoadjuvant combination immunotherapy
《World Journal of Gastrointestinal Surgery》2025年第1期41-49,共9页Yue-Gang Li Cheng-Cheng Han Meng Zhuang Wei Zhao Gang Hu Wen-Long Qiu Xi-Shan Wang Jian-Qiang Tang 
Supported by the National Natural Science Foundation of China,No.82072732.
BACKGROUND Endoscopy allows for the direct observation of primary tumor characteristics and responses after neoadjuvant treatment.However,reports on endoscopic evaluation following neoadjuvant immunotherapy remain lim...
关键词：Colorectal neoplasms ENDOSCOPY Neoadjuvant combination immunotherapy Response evaluation Mismatch repair status 
Neoadjuvant immunotherapy for non-small cell lung cancer:Opportunities and challenges
《Chinese Medical Journal Pulmonary and Critical Care Medicine》2024年第4期224-239,共16页Junjie Hu Jing Zhang Shiyue Wan Peng Zhang 
supported by the National Natural Science Foundation of China(Nos.82125001 and 82473368);the Innovation Program of Shanghai Municipal Education Commission(No.2023ZKZD33);Shanghai Pulmonary Hospital(Nos.FKCX2304 and FKLY20004).
Immune checkpoint inhibitors(ICIs)have transformed the treatment landscape for resectable non-small cell lung cancer.Numerous trials have explored the use of ICIs,either as monotherapy or in combination with other the...
关键词：Lung cancer Neoadjuvant immunotherapy Combinatorial therapy BIOMARKER Tumor microenvironment 
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma:a phase Ib trial
《Signal Transduction and Targeted Therapy》2024年第12期5777-5785,共9页Jiayong Liu Xuan Wang Zhongwu Li Shunyu Gao Lili Mao Jie Dai Caili Li Chuanliang Cui Zhihong Chi Xinan Sheng Yumei Lai Zhichao Tan Bin Lian Bixia Tang Xieqiao Yan Siming Li Li Zhou Xiaoting Wei Juan Li Jun Guo Lu Si 
supported by the National Key Research and Development Program(2023YFC2506404);National Natural Science Foundation of China(82372869,82272676,and 82073011);Beijing Municipal Administration of Hospitals’Ascent Plan(DFL20220901,QML20231107);Beijing Natural Science Foundation(7242021).
Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma(AM).This phase Ib trial study(Clinicaltrials.gov NCT04197882)assessed the efficacy and safety of the combination of n...
关键词：ADJUVANT MELANOMA surgery 
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus:NEOTAX,a phase 2 study被引量：2
《Signal Transduction and Targeted Therapy》2024年第11期5157-5165,共9页Liangyou Gu Cheng Peng Qiyang Liang Qingbo Huang Deqiang Lv Houming Zhao Qi Zhang Yu Zhang Peng Zhang Shichao Li Junnan Xu Luyao Chen Yongpeng Xie Jinhang Li Gang Guo Xu Zhang Baojun Wang Xin Ma 
supported by the National Natural Science Foundation of China(Nos.82373169,82273412,82372704).
The potential benefit of neoadjuvant toripalimab plus axitinib in cases with clear cell renal cell carcinoma(ccRCC)and inferior vena cava tumor thrombus(IVC-TT)remains unclear.NEOTAX was a phase 2 study to investigate...
关键词：THROMBUS unchanged PHASE 
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer:a multicentre,open-label,single-arm,phase 2 trial(TD-NeoFOUR trial)
《Signal Transduction and Targeted Therapy》2024年第11期5310-5318,共9页Hongtao Duan Changjian Shao Zhilin Luo Tianhu Wang Liping Tong Honggang Liu Xin Yao Jie Lei Jinbo Zhao Yuan Gao Tao Jiang Xiaolong Yan 
funded by the National Natural Science Foundation of China(Grant No.82173252);the Miaozi Talent Fund of Tangdu Hospital,Air Force Medical University.
This open-label,single-arm,phase 2 trial evaluated the efficacy and safety of neoadjuvant sintilimab combined with anlotinib and chemotherapy,followed by adjuvant sintilimab,for resectable NSCLC.Forty-five patients re...
关键词：CHEMOTHERAPY NEOADJUVANT PHASE 
Neoadjuvant sintilimab and apatinib combined with perioperative FLOT chemotherapy for locally advanced gastric cancer:A prospective,single-arm,phase Ⅱ study
《Chinese Medical Journal》2024年第21期2615-2617,共3页Huinian Zhou Bo Long Zeyuan Yu Junmin Zhu Hanteng Yang Changjiang Luo Wenjuan Zhang Chi Dong Xiaoying Guan Long Li Gengyuan Zhang Hongtai Cao Shigong Chen Linyan Zhou Qichen He Shiying Gan Xiangyan Jiang Qianlin Gu Keshen Wang Wengui Shi Long Qin Zuoyi Jiao 
supported by Jiangsu Hengrui Medicine Co.,Ltd.&Innovent Biologics(Suzhou)Co.,Ltd,the Fundamental Research Funds for the Central Universities of Lanzhou University(Nos.lzujbky-2022-ey04 and lzujbky-2023-eyt04);the Science and Technology Program of Gansu Province,China(Nos.21JR1RA144 and 22JR5RA961);the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital,China(Nos.CY2020-MS10 and CY2023-QN-A02).
For patients with locally advanced gastric cancer(LAGC),the effectiveness of perioperative chemotherapy can be significantly improved by adding programmed cell death protein 1(PD-1)inhibitors during the neoadjuvant ph...
关键词：CHEMOTHERAPY DEATH cancer 
全选清除导出
共28页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部